 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | LAT8881 / Lateral Pharma
Journal: Harnessing endogenous peptide compounds as potential therapeutics for severe influenza. (Pubmed Central) - Dec 7, 2023
These findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.
- || Review, Journal: Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials. (Pubmed Central) - Aug 30, 2023
AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN.
- || LAT8881 / Lateral Pharma
Trial completion: A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - Jul 31, 2023
P1, N=25, Completed, Sponsor: Lateral Pharma Pty Ltd
Hopefully, these trials will result in a better clinical management of PHN. Recruiting --> Completed
- | LAT8881 / Lateral Pharma
Trial completion date, Trial primary completion date: A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - Feb 3, 2023
P1, N=28, Recruiting, Sponsor: Lateral Pharma Pty Ltd
Recruiting --> Completed Trial completion date: Nov 2022 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Mar 2023
- || LAT8881 / Lateral Pharma
Enrollment open: A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - Jul 28, 2022
P1, N=28, Recruiting, Sponsor: Lateral Pharma Pty Ltd
Trial completion date: Nov 2022 --> Jun 2023 | Trial primary completion date: Sep 2022 --> Mar 2023 Not yet recruiting --> Recruiting
- || LAT8881 / Lateral Pharma
New P1 trial: A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - Mar 27, 2022
P1, N=28, Not yet recruiting, Sponsor: Lateral Pharma Pty Ltd
- ||| LAT8881 / Lateral Pharma
Trial completion: Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - Sep 2, 2020
P2a, N=52, Completed, Sponsor: Lateral Pharma Pty Ltd
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || LAT8881 / Lateral Pharma
Trial completion: A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine (clinicaltrials.gov) - Sep 2, 2020
P2, N=26, Completed, Sponsor: Lateral Pharma Pty Ltd
Active, not recruiting --> Completed Recruiting --> Completed
- || LAT8881 / Lateral Pharma
Enrollment closed: Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - Feb 12, 2020
P2a, N=55, Active, not recruiting, Sponsor: Lateral Pharma Pty Ltd
Recruiting --> Completed Recruiting --> Active, not recruiting
- || LAT8881 / Lateral Pharma
New P2 trial: A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine (clinicaltrials.gov) - Nov 5, 2019
P2, N=26, Recruiting, Sponsor: Lateral Pharma Pty Ltd
- | LAT8881 / Lateral Pharma
Enrollment open: Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - May 2, 2019
P2a, N=55, Recruiting, Sponsor: Lateral Pharma Pty Ltd
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | LAT8881 / Lateral Pharma
New P2a trial: Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - Mar 7, 2019
P2a, N=55, Not yet recruiting, Sponsor: Lateral Pharma Pty Ltd